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Abstract
Background: The detection of Brucellae in tissue specimens using PCR assays is difficult because the amount of 
bacteria is usually low. Therefore, optimised DNA extraction methods are critical. The aim of this study was to assess the 
performance of commercial kits for the extraction of Brucella DNA.
Methods: Five kits were evaluated using clinical specimens: QIAamp™ DNA Mini Kit (QIAGEN), peqGold™ Tissue DNA 
Mini Kit (PeqLab), UltraClean™ Tissue and Cells DNA Isolation Kit (MoBio), DNA Isolation Kit for Cells and Tissues (Roche), 
and NucleoSpin™ Tissue (Macherey-Nagel). DNA yield was determined using a quantitative real-time PCR assay 
targeting IS711 that included an internal amplification control.
Results: Kits of QIAGEN and Roche provided the highest amount of DNA, Macherey-Nagel and Peqlab products were 
intermediate whereas MoBio yielded the lowest amount of DNA. Differences were significant (p < 0.05) and of 
diagnostic relevance. Sample volume, elution volume, and processing time were also compared.
Conclusions: We observed differences in DNA yield as high as two orders of magnitude for some samples between 
the best and the worst DNA extraction kits and inhibition was observed occasionally. This indicates that DNA 
purification may be more relevant than expected when the amount of DNA in tissue is very low.
Background
Brucellosis is a 're-emerging' zoonosis with a worldwide
distribution caused by small fastidious Gram negative
bacteria of the genus Brucella. Patients present with non-
specific signs and symptoms such as inconstant fevers,
sweating, weakness, headaches, depression, weight loss,
and muscle and body pain. The disease can become
chronic with focal lesions which can affect various
organs. The cultivation and identification of Brucella spe-
cies with conventional microbiological techniques is
time-consuming and hazardous and should be performed
under BSL-3 conditions [1]. Real-time PCR assays allow
for the rapid and specific detection of Brucella species,
but the amount of bacteria in tissues and body fluids is
frequently extremely low [2,3]. Therefore, DNA extrac-
tion is a critical step to avoid false negative PCR results.
In general, blood and serum are regarded as valuable
specimens, but biopsies of focal lesions are more relevant
in chronic courses of the disease [4-6]. The material
obtained with biopsies is usually scarce and can contain
inhibitory components that make PCR diagnosis even
more difficult. The performance of commercial kits for
the preparation of DNA from serum has been evaluated
by Queipo-Ortuno et al. [7], but no systematic study has
been performed using clinical tissue specimens. There-
fore, the aim of this study was to compare the perfor-
mance of commercially available kits for the extraction of
Brucella DNA from infected tissues.
Methods
Samples and tissue homogenization
Organ samples were obtained from two dromedaries
fr om  Dubai , U nit ed Ar a b Em ir a t es ( U AE ),  wh ic h we r e
serological positive for brucellosis and had to be
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destroyed by UAE law (Ministerial degree of the UAE no.
132/2004). Both dromedaries were euthanized with T61
and samples were obtained from different organs (Tab. 1)
for the isolation of Brucella organisms as described previ-
ously [8]. Culture proved generalized Brucella melitensis
infections in both animals. Identification of the pathogen
was performed using conventional microbiological tech-
niques including species-specific AMOS PCR [9]. Six tis-
sue samples of each animal were used to assess the
performance of commercial DNA extraction kits. Ini-
tially, pieces of tissue (~5 g) were inactivated and pre-
served in formalin (10% v/v). Subsequently the specimens
were washed twice in deionized water (10 ml), and incu-
bated over night in 20 ml sterile physiological saline at
4°C. DNA extraction was done as described previously
[10]. In brief, the specimens were cut into small pieces
(~150 mg) and made up with PBS to 1 ml in a sampler
tube. The tubes were shaken in a FastPrep®-24 Instrument
(MP Biomedicals, Illkirch, France) at speed 5.0 for 20 s
according to the manufacturer's instructions and placed
on ice for further 20 s. This procedure was repeated five
times. The sampler tubes were then centrifuged at 14.000
rpm for 20 min at 4°C. DNA was prepared from 50 μl ali-
quots of the supernatant.
DNA purification methods
The five commercial kits used in this study are briefly
described below along with the modifications introduced
in each case to the manufacturer's instructions:
UltraClean™Tissue and Cells DNA Isolation Kit
(MoBio): The protocol was followed to step 9. The elution
(steps 10 to 12) was done using 100 μl TD3 buffer instead
of 50 μl.
PeqGold™Tissue DNA Mini Kit (PeqLab): The protocol
was followed from step 1 to step 7. Only the optional step
2 (RNase digestion) was not included. Elution was done
using 100 μl elution buffer instead of 200 μl.
QIAampDNA™Mini Kit (QIAGEN): The protocol for
tissue samples was followed including procedure 3a
(without RNase treatment described in 3b) to step 8, but
elution was done using 100 μl elution buffer.
DNA Isolation Kit for Cells and Tissues (Roche): The
procedure for DNA isolation from 100 mg - 1 g tissue was
followed as recommended by the manufacturer.
NucleoSpin™ Tissue (Macherey-Nagel): The protocol
for genomic DNA purification from tissue was used as
described by the manufacturer.
Real-time PCR
The amount of DNA was determined in triplicates using
a real-time PCR assay with hybridization probes targeting
the insertion sequence IS711, which is present in 6-7 cop-
ies per genome in Brucella abortus, melitensis, and suis.
An internal amplification control targeting bacteriophage
lambda DNA was included to determine inhibitory
effects of the sample matrix as described previously [11].
Primers and probes were designed based on alignment
studies using the BLAST program and the sequence data-
Table 1: Mean concentration of Brucella melitensis DNA obtained with five purification kits from tissue samples of two 
dromedaries.
QIAGEN Peqlab Macherey-Nagel MoBio Roche
fg/μl mean SD mean SD mean SD mean SD mean SD
D1452/06
Liver 8915 15150 186 17 76 9 neg 207 26
Spleen 10 2 5 2 101 21 neg* 402 20
Lung 225 66 72 11 216 55 71 23 2252 89
Right kidney 1377 19 73 27 315 24 101 19 757 53
Prescapular Ln 415 65 111 13 41 11 123 20 1338 355
Intestine 223 56 90 8 179 29 neg* 382 54
D1469/06
Spleen 484 426 57 4 38 7 neg* 67 67
Right kidney 235 23 10 8 14 3 3 3 111 29
Spinal Cord 289 64 11 1 126 33 neg* 14* 12
Pancreas 229 57 61 10 179 34 75 15 88* 14
Aorta lymph node 208 42 4 2 238 41 neg 112 11
Mammary Ln 355 299 140 26 297 12 465 60 112 18
(Ln, lymph node; SD, standard deviation; neg, negative Brucella PCR assay; *, negative inhibition control).Tomaso et al. BMC Infectious Diseases 2010, 10:100
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base of the National Centre for Biotechnology Informa-
tion. The oligonucleotides used for the Brucella specific
target were IS711_S TTGTCGATGCTATCGGCCTAC,
IS711_R GGCAATGAAGGCCCTTAAGT, IS711_FL
GAAGCTTGCGGACAGTCACCATAAT-fluorescein,
and IS711_LC LightCycler-Red-640-GCCGGGTGTTG-
GCTTTATTCG-phosphate. The oligonucleotides used
for the detection of the internal amplification control
were: Lambda_F ATGCCACGTAAGCGAAACA,
Lambda_R GCATAAACGAAGCAGTCGAGT, Lambda_
FL.ss CACTTCCCGAATAAC-fluorescein, and Lambda_
LC LightCycler-Red-705-CGGATATTTTTGATCTGAC
CGAAGCG-phosphate. Primers and probes were
o b t a i n e d  f r o m  a n d  d e s i g n e d  i n  c o o p e r a t i o n  w i t h  T I B
MOLBIOL (Berlin, Germany). A real-time hot-start PCR
was performed with the LightCycler FastStart DNA Mas-
ter Hybridisation Probes Kit™ (Roche Diagnostics, Man-
nheim, Germany) in a LightCycler Instrument™ (Roche
Diagnostics, Mannheim, Germany). The 20 μl reaction
mixture contained 3 mM MgCl2, 2 μl 10× LightCycler-
FastStart Reaction Mix Hybridisation Probes, 0.5 μl of
each primer (20 pmolμl-1), 0.5 μl of each hybridisation
probe (8 pmolμl-1) and 2 μl template. No-template con-
trols that contained 2 μl of PCR water instead of DNA
and positive controls that contained DNA of Brucella
melitensis were included in each run to detect any ampli-
con contamination or amplification failure. Reaction con-
ditions were: 10 min at 95°C, 45 cycles of 10 s at 95°C, 10 s
at 55°C and 15 s at 72°C. A melting curve analysis was
performed after the last amplification cycle with 95°C for
0 s, 45°C for 30 s, and 95°C for 0 s. Temperature change
rates were 20°Cs-1 for all but the melting curve analysis,
where the rate was 0.1°Cs-1. Data analyses were per-
formed with LightCycler software version 5.32. The auto-
mated second derivative maximum method was used for
standardized calculation of the threshold cycle number
(CT). Readout of LightCycler-Red 640 values was per-
formed in channel F2/F1 and readout of LightCycler-Red
705 values was performed in channel F3/F2. Cycle
threshold values were used to calculate the amount of
DNA that was prepared from the tissue samples. A posi-
tive result was assigned when at least two of the triplicate
reactions gave a CT value < 40 and the values were used
for further calculations. In order to generate a standard
curve for the quantification of Brucella DNA the concen-
tration of purified B. melitensis DNA was determined
spectrophotometrically using a NanoDrop ND-1000 UV-
Vis spectrophotometer (Nano-Drop Technologies, Wilm-
ington, DE, USA). This quantified DNA was used for
serial dilutions with PCR-grade water. Based on the full
bacterial genome sequence of B. melitensis published in
GenBank (accession numbers NC_003317 and
NC_003318), it was determined that each Brucella
genome copy (i.e., genome equivalent [GE]) amounts to
3.38 fg according to the following equation: GE (fg) =
number of base pairs per GE × 618 g mol-1 × 1015/6.023 ×
1023 mol-1 (Avogadro constant).
Statistics
Statistical analysis was performed using STATISTICA 7.1
(StatSoft Inc., Tulsa, OK 74104, USA) and Microsoft®
Office Excel 2003 (11.8105.8107) SP2. Significant differ-
ences between group values were determined by one-way
ANOVA at p ≤ 0.05. One-way ANOVA assumes that the
variances of the groups are all equal. Therefore a test for
homogeneity of variances was performed (Levene test,
data not shown). If the significance value exceeds 0.05,
the assumption that the variances are equal is justified. In
cases where differences among group means exist, post
hoc range tests and pair wise multiple comparisons were
performed (data not shown). For one-way ANOVA post
hoc tests the Scheffe test was used if equal variances were
shown. If equal variances could not be assumed the Dun-
nett's T3 test was used. A probit analysis to determine the
limit of detection was performed using PriProbit® 10 ver-
sion 1.63 designed by Dr. Masayuki Sakuma (Kyoto Uni-
versity, Kyoto, Japan, http://bru.gmprc.ksu.edu/proj/
priprobit/index.asp). The statistical significance was set
at a level of p = 0.05. The linear range of the insertion
sequence IS711-based real-time PCR was determined
according to the approved Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines for the evaluation of the
linearity of quantitative measurement procedures [12].
Seven equally spaced concentrations were analyzed with
eight replicates at each level. Based on a polynomial
method, two alternative statistical models (linear and
nonlinear) were assessed relative to which is most likely
to be true (1st-, 2nd- and 3rd- order least-squares regres-
sion). When a nonlinear polynomial fits the data better, it
was assessed if the difference between the best-fitting
nonlinear and linear polynomial is less than the amount
of allowable bias for the method. If necessary, corrections
(shortening of the linear range) were done and 1st-, 2nd-
and 3rd- order least-squares regression was conducted
again. The linear range was determined, when the linear
model fitted best. Based on a generated standard curve
(data not shown) the determined CT values of each sam-
ple were converted to quantitative results by using the
logarithmic transformed function y = -1.8573Ln(x) +
41.18 with y = generated CT value and x = unknown DNA
concentration.
Results
The detection limit of the real-time PCR assay was 2.35
genome equivalents per PCR reaction with a probability
of 95% as determined using Probit analyses. The linear
range was calculated to be 260 to 2.6 × 107 fg per reaction.Tomaso et al. BMC Infectious Diseases 2010, 10:100
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In order to detect inhibitory effects, a real-time PCR
assay was incorporated specifically detecting bacterio-
phage λ-DNA as described previously (Table 1) [10]. The
melting points measured for IS711 and the bacteriophage
λ-DNA target were at approximately 64°C and 50°C,
respectively.
Comparison of DNA yield obtained with the kits tested
in this study showed significant differences as determined
by one-way ANOVA (p < 0.05). Kits of QIAGEN and
Roche provided the highest amount of DNA (Table 1),
Macherey-Nagel and Peqlab products were intermediate
whereas MoBio yielded the lowest amount of DNA. We
also observed differences in Brucella melitensis DNA
content between organs. One-way ANOVA (p < 0.05)
showed significant differences of the mean between the
amount of DNA in pancreas and the right mammary
lymph node of dromedary D1469/06. In animal D1452/06
we found a significantly higher bacterial concentration in
the right kidney than in spleen tissue. Inhibition of the
PCR and/or insufficient DNA yield was observed with
liver, spleen, intestine, lymph node, and spinal cord tissue
preparations using the MoBio kit leading to negative
results. Preparations of spinal cord and pancreatic tissues
extracted using the Roche kit showed inhibition of the
internal amplification control and also low DNA yield.
For the selection of a DNA extraction method several fac-
tors besides the recovery of DNA and the elimination of
inhibitory substances have to be considered for practical
and economic reasons. Table 2 displays sample volume,
elution volume, and processing time for each extraction
method. All kits can be handled easily, but the hands-on
time ranges from 30 min to 3 hrs 30 min (Table 2).
Discussion and Conclusions
The diagnosis of brucellosis is challenging as culture of
Brucellae and sero-conversion require weeks. Nucleic
acid amplification methods might circumvent this diag-
nostic window, but the very low amount of DNA in tissue
samples obviates reliable rapid detection using real-time
or conventional PCR techniques. Real-time PCR assays
are rapid, specific and have a very low limit of detection,
when multi-copy gene targets are used. However, in our
experience with clinical samples even highly efficient and
sensitive real-time PCR assays frequently fail to detect
bacterial DNA due to the extremely low number of bacte-
ria in tissues. For this reason, the aim of this study was to
evaluate commercially available DNA extraction kits that
should provide high DNA yields and reduce inhibition to
improve the results that can be obtained with real-time
PCR assays. Based on our experience formalin should be
eliminated as much as possible in order to detect even the
smallest amounts of target DNA. Therefore, we regarded
washing steps and long incubation in saline an indispens-
able prerequisite. We have decided to test samples from
naturally infected animals, because this allowed us to test
several organs in parallel and to obtain enough tissue to
evaluate a panel of kits. Due to the small amount of bacte-
ria in some samples the DNA yield was sometimes out of
the linear range of this real-time PCR assay which reflects
the situation under real clinical conditions. Except for
one kit (MoBio) all kits yielded enough DNA to regularly
provide positive results in real-time PCR assays. The
QIAGEN kit provided the highest DNA yield in half of
the samples. The Roche kit can be advantageous when
relatively large amounts of tissue need to be processed.
W e have observed differences in DNA yield as high as
two orders of magnitude for some samples between the
best and the worst DNA extraction kits in this study. This
indicates that DNA purification may be more relevant
than expected, especially, when the amount of DNA in
tissue is very low. Optional RNase steps were performed
in none of the assays as the reagents were not supplied
with the kits and RNA does not inhibit the PCR reac-
tions. In order to provide identical amounts of DNA elu-
ate the amount of elution buffer was adjusted to 100 μl for
all kits. It cannot be excluded that these minor changes of
Table 2: Characteristics of DNA extraction kits.
Company MoBio
(Dianova)
Roche QIAGEN Peqlab Macherey Nagel
Kit UltraClean™ Tissue and 
Cells DNA Isolation Kit
DNA Isolation Kit for 
Cells and Tissues
QIAamp™ DNA Mini Kit PeqGOLD™ Tissue
DNA Mini Kit
NucleoSpin™ Tissue
Cat. number 12334-250 11814770001 51306 12-3396-02 740952.250
Number of 
preparations
250 10 250 200 250
Sample size [mg] 1-25 400 25 30 1-25
Elution volume [μL] 50 1000 50-200 50-200 60-100
Processing time 
(hrs:min)
00:15 02:30 02:30 03:20 03:15Tomaso et al. BMC Infectious Diseases 2010, 10:100
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the purification procedure have adversely influenced the
DNA yield of certain kits. In the animals used for this
study we observed significant differences in DNA content
among different organs. General recommendations
regarding favorable tissue samples cannot be given and
results obtained from specimens of focal lesions can only
be part of a polyphasic diagnostic approach. Further
studies in a clinical setting are warranted to assess,
whether the use of these DNA preparation methods will
actually help to improve the clinical usefulness of real-
time PCR assays for the detection of Brucellae in tissue.
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